Author

Jean-Luc Re Canon

Observed names: Canon, Jean-Luc, J. Canon, J.L. Canon, Jean-Luc Canon, Jean-Luc. Canon, JeanLuc Canon, Jean‐Luc Canon

Observed institutions: Dartmouth College, National Health Service, Mount Sinai Hospital, Cliniques Universitaires Saint-Luc, Amgen (United States), Royal Marsden NHS Foundation Trust, Vrije Universiteit Brussel, University of California, Los Angeles, Universidad de Salamanca, Ludwig Cancer Research, Universitair Ziekenhuis Leuven, Beatson West of Scotland Cancer Centre, Ghent University Hospital, Institut Jules Bordet, Institut Gustave Roussy, Erasmus Hospital, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Centre Georges François Leclerc, Institute of Pathology and Genetics, Marqués de Valdecilla University Hospital, Centre Eugène Marquis, Hospital Clínic de Barcelona, Ludwig Cancer Research, Unified Szent István and Szent László Hospital, München Klinik, Royal Marsden Hospital, Centre François Baclesse, Vall d'Hebron Hospital Universitari, Institut Claudius Regaud, Centre Hospitalier Universitaire de Liège, Grand Charleroi Hospital, München Klinik Neuperlach, Institut Sainte Catherine, Dartmouth Cancer Center, Fondation Gustave Roussy, Institut Curie, UCLouvain, KU Leuven

ORCID: 0009-0000-3016-9323

Observed ORCID: 0009-0000-3016-9323

OpenAlex ID: A5110044973

Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

2007 · Eric Van Cutsem, Marc Peeters, et al. · Journal of Clinical Oncology · 1,981

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

2010 · Jean-Yves Douillard, Salvatore Siena, et al. · Journal of Clinical Oncology · 1,809

PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer

2014 · Lee S. Schwartzberg, Fernando Rivera, et al. · Journal of Clinical Oncology · 635

Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial

2006 · Henri Roché, Pierre Fumoleau, et al. · Journal of Clinical Oncology · 578

PDF

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

2018 · Marina Chiara Garassino, Byoung-Chul Cho, et al. · The Lancet Oncology · 568

PDF

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

2022 · C.E. Geyer, J.E. Garber, et al. · Annals of Oncology · 480

PDF

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

2022 · François-Clément Bidard, François-Clément Bidard, et al. · The Lancet Oncology · 353

Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial

2009 · Marc Spielmann, Henri Roché, et al. · Journal of Clinical Oncology · 298

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer

2015 · Johan F. Vansteenkiste, Jean-Luc Canon, et al. · Journal of Thoracic Oncology · 162

Neutrophil:Lymphocyte Ratio and Intraoperative Use of Ketorolac or Diclofenac are Prognostic Factors in Different Cohorts of Patients Undergoing Breast, Lung, and Kidney Cancer Surgery

2013 · Patrice Forget, Jean-Pascal Machiels, et al. · Annals of Surgical Oncology · 161

Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma

2017 · Fernando Rivera, Meinolf Karthaus, et al. · International Journal of Colorectal Disease · 135

PDF

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

2016 · David Miles, David Cameron, et al. · European Journal of Cancer · 126

Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications

2019 · Pascal Jézéquel, Olivier Kerdraon, et al. · Breast Cancer Research · 118

PDF

Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study

2023 · Yoshiaki Nakamura, Nobumasa Mizuno, et al. · Journal of Clinical Oncology · 109

PDF

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

2023 · H. Borghaei, F. de Marinis, et al. · Annals of Oncology · 103

PDF

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer

2018 · Eric Van Cutsem, Manuel Hidalgo, et al. · International Journal of Cancer · 103

PDF

Randomized, Double-Blind, Active-Controlled Trial of Every-3-Week Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia

2006 · Jean-Luc Canon, Johan Vansteenkiste, et al. · JNCI Journal of the National Cancer Institute · 103

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma

2015 · Jacques De Grève, Teresa Moran, et al. · Lung Cancer · 91

Oral mucositis induced by anticancer treatments: physiopathology and treatments

2006 · Lionel D'Hondt, Christophe Lonchay, et al. · Therapeutics and Clinical Risk Management · 87

PDF

Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?

2007 · Catherine Hubert, Christine Sempoux, et al. · Liver International · 73

Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial

2013 · Lise Roca, Véronique Diéras, et al. · Breast Cancer Research and Treatment · 70

Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies

2019 · Lorraine Springuel, Caroline Lonez, et al. · BioDrugs · 68

PDF

Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)

2007 · Rosa Giuliani, Virginie Durbecq, et al. · European Journal of Cancer · 58

A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial

2021 · Rachel Galot, Christophe Le Tourneau, et al. · European Journal of Cancer · 57

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1

2022 · Frédérique Berger, Margaux Marce, et al. · BMJ Open · 48

PDF

Works count: 148

Citation count: 9,589

H-index: 33

I10-index: 68